Abbott Laboratories (ABT)
After hours:
| Previous close | 123.82 |
| Open | 123.08 |
| Bid | 123.45 x 1000 |
| Ask | 123.59 x 800 |
| Day's range | 121.59 - 124.62 |
| 52-week range | 105.36 - 142.60 |
| Volume | |
| Avg. volume | 5,721,922 |
| Market cap | 218.95B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 30.59 |
| EPS (TTM) | 4.03 |
| Earnings date | 26 Jan 2022 |
| Forward dividend & yield | 1.88 (1.52%) |
| Ex-dividend date | 13 Jan 2022 |
| 1y target est | 145.18 |
- Zacks
Is a Surprise Coming for Abbott (ABT) This Earnings Season?
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Motley Fool
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Abbott is a major pharmaceutical company best known for its medical devices, diagnostics, and pediatric and adult nutritional products -- think Pedialyte or Similac. This year, it's being crowned as a dividend king -- meaning the company has increased its annual dividend for 50 consecutive years. Excluding COVID-testing-related sales, Abbott still boasts a nearly 12% increase over pre-pandemic 2019 sales for the quarter.
- Motley Fool
3 Things About Abbott Laboratories That Smart Investors Know
When it comes to underrated healthcare stocks that smart investors love, Abbott Laboratories (NYSE: ABT) takes the cake. On the contrary, it's exactly Abbott's willingness to compete in these spaces that makes the company one of the sturdiest. Given that Abbott has a market cap of about $238 billion and trailing revenue of $42.3 billion, it shouldn't surprise anyone that the business sometimes struggles to grow as aggressively as a smaller competitor might.
